Leighton Welch increased its stake in Oracle Corp (ORCL) by 37.09% based on its latest 2017Q3 regulatory filing with the SEC. Welch Capital Partners Llc bought 40,910 shares as the company’s stock rose 5.35% with the market. The hedge fund run by Leighton Welch held 151,201 shares of the prepackaged software company at the end of 2017Q3, valued at $7.31 million, up from 110,291 at the end of the previous reported quarter. Welch Capital Partners Llc who had been investing in Oracle Corp for a number of months, seems to be bullish on the $195.72B market cap company. The stock decreased 0.51% or $0.24 during the last trading session, reaching $47.28. About 9.75M shares traded. Oracle Corporation (NYSE:ORCL) has risen 14.08% since December 31, 2016 and is uptrending. It has underperformed by 2.62% the S&P500.
Juncture Wealth Strategies Llc decreased its stake in Supernus Pharmaceuticals Inc (SUPN) by 29.79% based on its latest 2017Q3 regulatory filing with the SEC. Juncture Wealth Strategies Llc sold 11,015 shares as the company’s stock rose 29.12% with the market. The institutional investor held 25,958 shares of the health care company at the end of 2017Q3, valued at $1.04M, down from 36,973 at the end of the previous reported quarter. Juncture Wealth Strategies Llc who had been investing in Supernus Pharmaceuticals Inc for a number of months, seems to be less bullish one the $2.04 billion market cap company. The stock decreased 2.33% or $0.95 during the last trading session, reaching $39.85. About 344,899 shares traded. Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) has risen 91.80% since December 31, 2016 and is uptrending. It has outperformed by 75.10% the S&P500.
Among 38 analysts covering Oracle (NYSE:ORCL), 27 have Buy rating, 0 Sell and 11 Hold. Therefore 71% are positive. Oracle had 102 analyst reports since July 30, 2015 according to SRatingsIntel. The rating was maintained by Credit Suisse on Friday, September 15 with “Buy”. The firm has “Outperform” rating given on Thursday, June 22 by RBC Capital Markets. Macquarie Research initiated it with “Outperform” rating and $46 target in Tuesday, April 26 report. Wedbush maintained the shares of ORCL in report on Thursday, March 30 with “Neutral” rating. BMO Capital Markets maintained it with “Outperform” rating and $57 target in Thursday, June 22 report. The stock has “Buy” rating by SunTrust on Wednesday, September 16. The stock has “Buy” rating by Jefferies on Tuesday, October 17. On Thursday, June 22 the stock rating was maintained by UBS with “Buy”. The stock of Oracle Corporation (NYSE:ORCL) earned “Market Perform” rating by BMO Capital Markets on Friday, January 8. The firm earned “Buy” rating on Wednesday, March 16 by UBS.
Welch Capital Partners Llc, which manages about $347.76 million and $296.79 million US Long portfolio, decreased its stake in Delta Airlines Inc (NYSE:DAL) by 7,580 shares to 186,280 shares, valued at $8.98M in 2017Q3, according to the filing. It also reduced its holding in Pandora Media Inc (NYSE:P) by 132,460 shares in the quarter, leaving it with 817,230 shares, and cut its stake in Cl C.
Investors sentiment increased to 1.13 in Q3 2017. Its up 0.18, from 0.95 in 2017Q2. It is positive, as 67 investors sold ORCL shares while 498 reduced holdings. 122 funds opened positions while 519 raised stakes. 2.32 billion shares or 1.54% less from 2.35 billion shares in 2017Q2 were reported. Archford Cap Strategies Limited Com accumulated 11,731 shares. Ferguson Wellman Capital Incorporated, a Oregon-based fund reported 7,176 shares. Eqis Capital Management invested in 0.13% or 47,422 shares. 1,427 are held by Finance Management. State Treasurer State Of Michigan owns 916,360 shares. Eaton Vance Mngmt holds 4.83 million shares or 0.6% of its portfolio. Century Cos invested 0.62% of its portfolio in Oracle Corporation (NYSE:ORCL). Andra Ap accumulated 0.25% or 219,700 shares. Orrstown Fin Services owns 2,740 shares or 0.15% of their US portfolio. State Board Of Administration Of Florida Retirement Systems holds 4.26 million shares or 0.56% of its portfolio. Bnp Paribas Arbitrage Sa reported 0.32% in Oracle Corporation (NYSE:ORCL). Moreover, Oarsman has 0.45% invested in Oracle Corporation (NYSE:ORCL). 34.41M are held by Franklin. Virtu Fin Llc has 22,401 shares. Rmb Cap Mngmt Limited Company, a Illinois-based fund reported 14,282 shares.
Among 10 analysts covering Supernus Pharmaceuticals (NASDAQ:SUPN), 7 have Buy rating, 0 Sell and 3 Hold. Therefore 70% are positive. Supernus Pharmaceuticals had 34 analyst reports since August 26, 2015 according to SRatingsIntel. Cantor Fitzgerald maintained the shares of SUPN in report on Wednesday, September 27 with “Buy” rating. The firm has “Outperform” rating by Northland Capital given on Wednesday, October 28. Jefferies maintained Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) on Thursday, August 4 with “Buy” rating. The stock has “Buy” rating by Stifel Nicolaus on Wednesday, November 8. The firm has “Neutral” rating given on Monday, July 17 by PiperJaffray. The stock has “Neutral” rating by Piper Jaffray on Monday, July 18. As per Monday, December 4, the company rating was upgraded by Janney Capital. The firm has “Outperform” rating by Northland Capital given on Thursday, November 5. The stock of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) has “Buy” rating given on Wednesday, October 18 by FBR Capital. The stock of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) has “Buy” rating given on Monday, September 18 by Cantor Fitzgerald.
Since August 16, 2017, it had 0 insider buys, and 4 selling transactions for $7.22 million activity. Schwabe Stefan K.F. also sold $4.43M worth of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) on Thursday, September 7. PATRICK GREGORY S sold $2.38 million worth of stock.
Analysts await Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) to report earnings on February, 27. They expect $0.26 EPS, 0.00% or $0.00 from last year’s $0.26 per share. SUPN’s profit will be $13.33M for 38.32 P/E if the $0.26 EPS becomes a reality. After $0.29 actual EPS reported by Supernus Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -10.34% negative EPS growth.
The post Oracle (ORCL) Shareholder Welch Capital Partners Has Upped Stake; Supernus Pharmaceuticals (SUPN) Holder Juncture Wealth Strategies Has Lowered Holding as Stock Price Rose appeared first on Stock Market News | HillCountryTimes | Get it Today.
from
https://www.hillcountrytimes.com/2017/12/31/oracle-orcl-shareholder-welch-capital-partners-has-upped-stake-supernus-pharmaceuticals-supn-holder-juncture-wealth-strategies-has-lowered-holding-as-stock-price-rose/
No comments:
Post a Comment